Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea Biotherapeutics, Inc. (not Spyre Therapeutics, Inc.) on June 18, 2021. The registrant is a Delaware corporation with its principal executive offices in Austin, Texas, and its common stock trades on the Nasdaq Global Market under the symbol "AGLE". The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the appointment of Marcio Souza as a Class II director and a member of the Compensation Committee, effective June 18, 2021. Mr. Souza brings significant experience from his roles as President and CEO of Praxis Precision Medicines, Inc., and previously as COO of PTC Therapeutics, Inc.
Compensation and Governance Details
- Director Retainer: Mr. Souza will receive a pro rata portion of the $40,000 annual director retainer and a pro rata portion of the $7,500 annual Compensation Committee retainer for the remainder of the year.
- Stock Option Grant: The Board granted Mr. Souza an option to purchase 60,000 shares of common stock. The exercise price equals the closing sale price on June 18, 2021. The option vests monthly over three years, contingent on continued service.
- Indemnification: The Company entered into its standard form of indemnification agreement with Mr. Souza.
Investor Verification Checklist
- Verify the trading symbol "AGLE" corresponds to Aeglea Biotherapeutics, Inc., not Spyre Therapeutics, Inc.
- Confirm the vesting schedule and exercise price of the 60,000-share option granted to Marcio Souza.
- Review the Company's existing compensation policy for non-employee directors to validate the pro rata retainer calculations.
- Check for any subsequent filings regarding Mr. Souza's continued service or changes to the Compensation Committee composition.